Table 1.
Patients’ characteristics
| Parameters | Control group (n = 192) | PTX group (n = 112) | P value |
|---|---|---|---|
| Age (years) | 65.5 ± 7.1 | 64.7 ± 7.3 | 0.353 |
| Gender (Male/Female) | 113/79 | 78/34 | 0.060 |
| BMI (kg/m2) | 22.3 ± 3.3 | 22.9 ± 3.0 | 0.106 |
| Hypertension (n/%) | 133 (69.3) | 87 (77.7) | 0.114 |
| Diabetes mellitus (n/%) | 44 (22.9) | 20 (17.9) | 0.297 |
| Hyperlipidemia (n/%) | 69 (55.9) | 44 (39.3) | 0.560 |
| Hyperuricemia (n/%) | 57 (29.7) | 39 (34.8) | 0.353 |
| Heart failure (n/%) | 18 (9.4) | 16 (14.3) | 0.190 |
| Duration of dialysis (months) | 35 (28‐51) | 44 (34‐65) | 0.008 |
| Kt/V | 1.6 ± 0.5 | 1.7 ± 0.5 | 0.193 |
| Ultrafiltration rate (mL/min) | 6.6 ± 2.2 | 7.0 ± 2.1 | 0.117 |
| iPTH (pg/mL) | 1085 ± 533 | 1636 ± 724 | <0.001 |
| Ca (mg/dL) | 9.40 ± 1.21 | 9.89 ± 1.42 | 0.003 |
| P (mg/dL) | 6.95 ± 1.38 | 7.17 ± 1.26 | 0.158 |
| FGF‐23 (pg/mL) | 589 ± 190 | 635 ± 181 | 0.093 |
| Hb (g/dL) | 11.8 ± 2.6 | 11.2 ± 2.1 | 0.049 |
| CRP (mg/L) | 10.6 (4.1‐17.2) | 12.2 (5.2‐20.9) | 0.142 |
| ALB (g/L) | 36.7 ± 6.0 | 35.9 ± 5.5 | 0.238 |
| ALT (u/L) | 49.2 ± 27.5 | 53.8 ± 21.4 | 0.106 |
| AST (u/L) | 60.5 ± 18.3 | 66.3 ± 22.7 | 0.022 |
| ALP (u/L) | 267.8 ± 85.2 | 289.4 ± 116.3 | 0.087 |
| SUA (mg/dL) | 7.3 ± 2.2 | 7.7 ± 2.1 | 0.117 |
Data were presented as mean ± SD, median (25th‐75th quantiles) or count (percentage). Comparison was determined by t test, Wilcoxon rank sum test or Chi‐square test. P value < 0.05 (presented with bold font) was considered statistically significant. ALB, albumin; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; Ca, calcium; CRP, C‐reactive protein; FGF‐23, fibroblast growth factor 23; Hb, hemoglobin; iPTH, intact parathyroid hormone; P, phosphorus; PTX, parathyroidectomy; SUA, serum uric acid.